The science…or not behind deferrals of blood donors with a history of cancer
Transfusion · 2023-08 · 63 (8) · 1538-1545
DOI: 10.1111/trf.17467 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transfusion, online erschienen am 19.07.2023. Verfasst von Richard R Gammon und 5 weiteren Autor:innen. Beteiligte Einrichtung: OneBlood, Scientific, Medical, Technical Direction, Orlando, Florida, USA. Hauptthemen laut MEDLINE: Blood Donors, Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 26 Literaturangaben.
Abstract (Originalsprache)
Background
In the United States (US), each blood center's medical director sets policy for donors with a cancer history. Study Design and Methods A subgroup of America's Blood Centers' (ABC) Scientific, Medical, and Technical Committee developed a survey to measure the determination of eligibility, policies for deferral and/or lookback when a donor reports a current diagnosis or history of cancer. A 31‐question survey was sent to 47 ABC blood centers in North America via email. Survey results were compiled and literature evaluating the risk of cancer transmission by transfusion was reviewed.
Results
Responses were received from 37 centers (79%). Donors with a history of carcinoma or sarcoma who had completed treatment were accepted at 73% of centers with no further deferral. Donors with a history of leukemia or lymphoma were permanently deferred at 76% of centers. Donors with a myelodysplastic or myeloproliferative syndrome were deferred permanently at 86% of centers. Handling of donors with high white cell counts varied. Donors with cancer not in active treatment (i.e., prostate cancer) were subject to various deferrals. Center response to post‐donation reports of cancer vary widely. Literature review yielded no evidence of transfusion‐transmitted cancer.
Conclusion
Cancer deferral policies vary widely among blood centers, and are not generally based on evidence, but on some aspect of the precautionary principle. As the donor population ages and so becomes more at risk of cancer, this approach may further reduce the available donor pool.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- OneBlood, Scientific, Medical, Technical Direction, Orlando, Florida, USA.
- Donor Cancer Deferral Workgroup, America's Blood Centers, Washington, DC, USA.
- Vitalant, Corporate Medical Affairs, Charleston, South Carolina, USA.
- Transfusion Medicine, University of California Irvine, Orange, California, USA.
- Gulf Coast Regional Blood Center, Houston, Texas, USA.
- Carter BloodCare, Bedford, Texas, USA.
ORCID-Profile: Richard R Gammon, Merlyn Sayers
Zitieren
APA
Gammon, R. R., Hopkins, C., Mathur, G., Rossmann, S. N., Sayers, M., & Straus, T. (2023). The science…or not behind deferrals of blood donors with a history of cancer. Transfusion, 63(8), 1538-1545. https://doi.org/10.1111/trf.17467
Vancouver
Gammon RR, Hopkins C, Mathur G, Rossmann SN, Sayers M, Straus T. The science…or not behind deferrals of blood donors with a history of cancer. Transfusion. 2023;63(8):1538-1545. doi:10.1111/trf.17467
BibTeX
@article{Gammon2023,
author = {Gammon, Richard R and Hopkins, Courtney and Mathur, Gagan and Rossmann, Susan N and Sayers, Merlyn and Straus, Todd},
title = {The science…or not behind deferrals of blood donors with a history of cancer},
journal = {Transfusion},
year = {2023},
volume = {63},
number = {8},
pages = {1538--1545},
doi = {10.1111/trf.17467}
}
EUVIMED